Title: SAT0363 ENTHESITIS BUT NOT DACTYLITIS CONTRIBUTES TO BURDEN OF DISEASE IN PSA PATIENTS: DATA FROM THE BEPAS REAL LIFE COHORT
Abstract:<h3>Background</h3> Psoriatic arthritis (PsA) significantly impacts physical function and quality of life. Limited data are available to specifically evaluate the impact of the different disease domai...<h3>Background</h3> Psoriatic arthritis (PsA) significantly impacts physical function and quality of life. Limited data are available to specifically evaluate the impact of the different disease domains such as arthritis, axial involvement, skin disease, enthesitis and dactylitis. The BEPAS cohort, a prospective daily life cohort of PsA patients allows to study the impact of enthesitis and dactylitis on disease activity, disability and quality of life in PsA patients. <h3>Objectives</h3> 1) to measure the impact of enthesitis and dactylitis on health-related quality of life in PsA patients in Belgium. <h3>Methods</h3> At the inclusion visit, a cross-sectional analysis of dactylitis and enthesitis was performed among 462 patients from the BEPAS cohort and impact of enthesitis and/or dactylitis was studied. Patients were evaluated for the demographics, clinical disease manifestations, disability, disease global assessment and inflammatory markers at inclusion. Differences of tested variables between patients with and without dactylitis and/or enthesitis were evaluated by T-test or Chi –square testing. <h3>Results</h3> 462 patients (273 males and 189 females) with a mean disease duration of 8.53 years (SD: 9.25yrs) were recruited in 17 BEPAS centers from December 2012 to July 2014. 111 patients had enthesitis and 63 patients had dactylitis at inclusion. 17 patients had both enthesitis and dactylitis. Results are summarized in the table below: <h3>Conclusion</h3> Enthesitis has a larger impact on Quality of Life and Health Status than dactylitis in PsA. Patients with enthesitis and dactylitis have higher joint scores but not higher markers of systemic inflammation than those without. <h3>Acknowledgement</h3> This study is financially supported by MSD Belgium <h3>Disclosure of Interests</h3> Kurt de Vlam Consultant for: Pfizer Inc, Consultant for: Johnson & Johnson, Rik Lories Consultant for: Abbvie, Celgene, Eli-Lilly, Janssen, Merck, Novartis, Pfizer, UCB, Serge Steinfeld: None declared, Filip van den Bosch Consultant for: AbbVie, BMS, Galapagos, Janssen, Lilly, Merck, Novartis, Pfizer and UCB, Speakers bureau: AbbVie, BMS, Janssen, Lilly, Merck, Novartis, Pfizer and UCB., Adrien Nzeusseu Toukap: None declared, Hermine Leroi Employee of: HL is a employee of MSD BelgiumRead More